Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
12.22B
Enterprise Value
15.26B
Income
633.63M
Sales
6.29B
Book/sh
12.26
Cash/sh
1.81
Employees
18362
IPO
Nov 16, 1999
P/E
19.90
Forward P/E
12.22
PEG
1.30
P/S
1.94
P/B
2.38
P/C
16.11
P/FCF
14.38
EV/EBITDA
9.14
EV/Sales
2.43
Quick Ratio
1.11
Current Ratio
2.14
Debt/Eq
0.73
LT Debt/Eq
0.62
Option/Short
Yes / Yes
EPS (ttm)
1.47
EPS next Y
2.39
EPS next Q
0.53
EPS this Y
7.52%
EPS next Y
8.91%
EPS next 5Y
9.41%
EPS past 3/5Y
41.40% 6.97%
Sales past 3/5Y
5.84% 6.10%
EPS Y/Y TTM
31.02%
Sales Y/Y TTM
5.26%
EPS Q/Q
4.72%
Sales Q/Q
3.61%
Insider Own
0.06%
Insider Trans
0.00%
Inst Own
13.53%
Inst Trans
-6.32%
ROA
5.82%
ROE
11.80%
ROIC
7.51%
Gross Margin
68.21%
Oper. Margin
17.05%
Profit Margin
10.08%
SMA20
5.88%
SMA50
3.43%
SMA200
-6.36%
Trades
Shs Outstand
424.66M
Shs Float
418.28M
52W High
37.51 -22.18%
52W Low
26.12 11.75%
Volatility
1.41% 1.53%
ATR (14)
0.51
RSI (14)
65.66
Beta
0.57
Rel Volume
0.70
Avg Volume
1.53M
Volume
301,743
Perf Week
4.70%
Perf Month
6.15%
Perf Quarter
-1.95%
Perf Half Y
-10.84%
Perf YTD
-11.03%
Perf Year
-20.09%
Perf 3Y
30.20%
Perf 5Y
-18.19%
Perf 10Y
-3.98%
Prev Close
29.32
Price
29.19
Change %
-0.44%
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
CEO & DirectorDr. Deepak S. Nath Ph.D.
Interim CFOMr. Pierre Palassian
President of Global OperationsMr. Paul Connolly
Head of Investor RelationsEmily Heaven
Group General Counsel & Company SecretaryMs. Helen Barraclough